



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

DV-B-120

Cat. No.:	HY-162485
Molecular Formula:	C ₂₃ H ₁₈ N ₂ O ₅ S ₂
Molecular Weight:	466.53
Target:	Dengue virus; Virus Protease
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DV-B-120 is a competitive inhibitor for dengue virus (DENV) with IC ₅₀ s of 5.35, 7.39, 10.49 and 8.58 μM, for DENV-1, DENV-2, DENV-3 and DENV-4, respectively, by inhibiting NS2B-NS3 protease. DV-B-120 exhibits antiviral activity through inhibition of DENV replication ^[1] .								
IC₅₀ & Target	IC ₅₀ : 5.35 μM (DENV-1), 7.39 μM (DENV-2), 10.49 μM (DENV-3), 8.58 μM (DENV-4)								
In Vivo	<p>DV-B-120 (1-10 mg/kg, b.i.d, intracerebral, 5 days) suppresses the mortality and associated illness symptoms in DENV-2 infected ICR suckling mice, through activation of interferon (IFN) and antiviral IFN-stimulated genes (ISGs)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>DENV-2 infected ICR suckling mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1-10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>every other day, for 3 injection, intracerebral injection</td> </tr> <tr> <td>Result:</td> <td>Improved the survival rate, prevented the life-threatening symptoms.</td> </tr> </table>	Animal Model:	DENV-2 infected ICR suckling mice ^[1]	Dosage:	1-10 mg/kg	Administration:	every other day, for 3 injection, intracerebral injection	Result:	Improved the survival rate, prevented the life-threatening symptoms.
Animal Model:	DENV-2 infected ICR suckling mice ^[1]								
Dosage:	1-10 mg/kg								
Administration:	every other day, for 3 injection, intracerebral injection								
Result:	Improved the survival rate, prevented the life-threatening symptoms.								

REFERENCES

[1]. Huang Y-J, et al., Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection. J Virol. 2024 Apr 16;98(4):e0125823.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA